
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical ointment containing bacitracin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products contain bacitracin only in combination with other active ingredients, as ophthalmic (eye) ointments; bacitracin first-aid ointments and creams for the skin are filed as over-the-counter monograph drugs.
Bases for this dose form are usually nonaqueous. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Bacitracin is a polypeptide antibiotic used on the skin and in the eye that a pharmacy may compound when a prescriber orders it.
Bacitracin is a mixture of related cyclic polypeptide antibiotics made by an organism of the Bacillus subtilis group. It stops susceptible bacteria, mainly gram-positive species such as staphylococci and streptococci, from building their cell walls. Bacitracin first aid ointment is sold without a prescription under the OTC monograph to help prevent infection in minor cuts, scrapes and burns. Prescription bacitracin zinc and polymyxin B sulfate ophthalmic ointment is indicated for superficial infections of the conjunctiva and cornea. StatPearls notes FDA approval of ophthalmic bacitracin for the same use, but Drugs@FDA lists the single-ingredient bacitracin ophthalmic ointment applications as discontinued. In 2020 FDA asked manufacturers to withdraw bacitracin for injection from the market; the request did not affect topical or ophthalmic products. A prescriber might order bacitracin compounded in a vehicle or combination that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Topical and ophthalmic bacitracin products have no boxed warning. The first aid label says not to use it in the eyes, over large areas of the body, or if you are allergic to any ingredient; ask a doctor first about deep or puncture wounds, animal bites or serious burns, and stop and ask if you need it longer than 1 week, the condition worsens, or a rash develops. StatPearls notes bacitracin often causes allergic contact dermatitis, anaphylaxis has been reported, and people sensitive to neomycin may also react. The ophthalmic label warns that eye ointments may slow corneal healing. StatPearls notes limited pregnancy data. LactMed considers it low risk while breastfeeding, but only creams or gels, not ointments, should go on the breast. Talk to your prescriber or pharmacist about side effects.
Bacitracin inhibits bacterial cell wall synthesis by preventing dephosphorylation of the lipid pyrophosphate carrier that moves peptidoglycan precursors across the cell membrane; it is bacteriostatic or bactericidal depending on concentration and organism. StatPearls lists activity against Staphylococcus, Streptococcus, Corynebacterium, Clostridium and Actinomyces species and some Neisseria, with most gram-negative organisms resistant; complexing with zinc improves stability. It is poorly absorbed after topical, ophthalmic or oral use but can be absorbed through burned, denuded or granulating skin. Protein binding is minimal, and after intramuscular use it was mainly excreted by the kidneys. Labeled products: OTC first aid bacitracin ointment (OTC monograph M004) and bacitracin zinc and polymyxin B sulfate ophthalmic ointment (ANDA). FDA requested withdrawal of bacitracin for injection, once indicated for infant pneumonia and empyema caused by staphylococci, citing nephrotoxicity and anaphylaxis. StatPearls cites an American Academy of Ophthalmology recommendation of ophthalmic bacitracin ointment for pediculosis palpebrarum, which is not an FDA-approved indication. Prolonged use may allow overgrowth of nonsusceptible organisms, including fungi. Dosing is per prescriber. Monitor for contact dermatitis, hypersensitivity and secondary infection; patch testing may help confirm allergy.
Wash your hands. Apply a thin layer to the affected area and rub in gently as your label directs. Do not cover with a bandage or wrap unless your prescriber tells you to. Keep it out of your eyes. Do not apply to open wounds or broken skin unless told to. Wash your hands after applying.
Ointments are usually nonaqueous, so a USP <795> default beyond-use date of up to 180 days may apply when no other data exist. Store in the closed container at room temperature, away from heat and direct light, keep from freezing, and keep out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)